Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 5/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969055 | 1.00 | VSIR (0.47) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL24086186 | 1.00 | VSIR (0.47) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL19969098 | 1.00 | VSIR (0.47) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL21377529 | 0.89 | VSIR (0.44) | VSIRCD274LMNATSHR | |
| SCHEMBL18735673 | 0.85 | CD274 (0.65) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL20626602 | 0.85 | CD274 (0.65) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL20057309 | 0.85 | CD274 (0.65) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL16557045 | 0.85 | CD274 (0.65) | VSIRCD274SRCZAP70LMNA | |
| SCHEMBL21738408 | 0.83 | VSIR (0.50) | VSIRCD274SRCZAP70 | |
| SCHEMBL16557043 | 0.83 | CD274 (0.55) | VSIRCD274SRCZAP70LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379024-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | AURIGENE ONCOLOGY LIMITED (IN) | 2021-12-09 | — | — | US | disclosed |
| WO-2019175799-A2 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2018047139-A1 | COMPOUNDS AS MODULATORS OF TIGIT SIGNALLING PATHWAY | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379024-A1 | METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS | PDCD1, CD274, PDCD1LG2 | VSIR 1596/4885CD274 2/4885SRC 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.